Skip to content
Buy This GLP
← Research
Evidence

Can You Take a GLP-1 With Antipsychotics? Weight and Safety Evidence

Trials found weight loss when GLP-1 treatment was added to antipsychotics. See what researchers measured about psychiatric symptoms and what the labels say about oral medicines.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
Pooled weight difference versus control−6.74 kg95% confidence interval −10.05 to −3.43 kg8 randomized trials, 664 participants overall

A 2026 review pooled eight randomized trials with 664 participants receiving antipsychotics. The mean difference in weight was −6.74 kg compared with control (95% confidence interval, −10.05 to −3.43 kg). Nausea, vomiting, and constipation were more common with GLP-1 treatment. If you are reviewing GLP-1 side effects with your prescribers, mention any symptoms you already have so they can plan how to monitor changes.[1]

What trials measured about psychiatric symptoms

HISTORI randomized 154 adults with schizophrenia, prediabetes, and overweight or obesity who were on stable second-generation antipsychotic treatment. At 30 weeks, semaglutide reduced weight by 9.21 kg more than placebo. Researchers found no statistically significant group difference in the PANSS-6 schizophrenia symptom score or mental quality of life. A few people receiving semaglutide had more frequent hospitalizations. The study found no statistically significant difference in serious adverse events overall.[2]

COaST randomized 31 adults with schizophrenia and obesity who were taking clozapine. At 36 weeks, the trial found no group differences in schizophrenia symptom scores or in clozapine and norclozapine concentrations. The two trials provide information about the groups they studied. Their size and follow-up leave uncertainty about uncommon events and longer-term outcomes.[3]

Medication review and follow-up

The guide to lab monitoring during GLP-1 treatment explains common tests. Both the Wegovy and Zepbound labels warn that delayed stomach emptying can affect how oral medicines are absorbed. The labels call for attention to medicines that need close monitoring.[4][5]

Ask the clinicians managing both treatments what they want to track for your particular medicines, and consult them before changing either prescription.

Frequently asked

Can you take a GLP-1 with an antipsychotic?
Clinical trials have studied adding a GLP-1 in selected patients. Ask both prescribers to review your specific medicines and agree on what to monitor.
Did the trials measure psychiatric symptoms?
HISTORI and COaST measured schizophrenia symptoms and found no statistically significant differences between semaglutide and placebo during follow-up. The results leave uncertainty about longer-term outcomes.

Sources

  1. [1] Moubarak ES, et al. (2026). Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials Journal of Psychopharmacology. PMID 42746999
  2. [2] Ganeshalingam AA, et al. (2025). Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial JAMA Psychiatry. Source
  3. [3] Siskind D, et al. (2025). Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator-blinded, randomised controlled trial in Australia The Lancet Psychiatry. PMID 40506208
  4. [4] Novo Nordisk (2026). Wegovy (semaglutide) prescribing information DailyMed, U.S. National Library of Medicine. Source
  5. [5] Eli Lilly and Company (2026). Zepbound (tirzepatide) prescribing information DailyMed, U.S. National Library of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence